STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
16
Codes C/M, not in net · $993.6K priced
What the filings say about CHYM
Insiders, 180 days
-$1.2B net sold
9 sellers · 4% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$104.7M
31 notices
Chime Financial insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Chime Financial, Inc. insiders sold a net $1.2B of stock across 340 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Nobody has filed for crossing 5%. That is a fact, not missing data.
CHYM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
KING FAMILY TRUST
Filed 2026-10-13
$2.3M
KING FAMILY TRUST
Filed 2026-10-09
$1.4M
CROSSLINK VENTURES VII HLDGS, LLC
Filed 2026-09-16
$5.3M
CROSSLINK CROSSOVER FUND VI, LP
Filed 2026-09-16
$3.0M
CROSSLINK CROSSOVER FUND VII, LP
Filed 2026-09-16
$1.7M
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$98.9M
$83.5M
$26.2M
-32%
+22%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.2B sold by insiders over 180 days, $104.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CHYM
FY Dec 2025
$2.2B
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
$669.8M
Mar 2026
$647.4M
Dec 2025
$596.4M
Sep 2025
$543.5M
Jun 2025
$528.1M
Mar 2025
$518.7M
Dec 2024
$475.2M
Sep 2024
$421.9M
At each fiscal year end
Single quarter
Net margin, TTM
-0.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CHYM
FY Dec 2025
-46.2%
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
+4.2%
Mar 2026
+8.3%
Dec 2025
-7.5%
Sep 2025
-10.1%
Jun 2025
-174.8%
Mar 2025
+2.5%
Dec 2024
-4.1%
Sep 2024
-5.2%
At each fiscal year end
Single quarter
Free cash flow, TTM
$312.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CHYM
FY Dec 2025
$32.9M
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
$197.5M
Mar 2026
$80.9M
Dec 2025
$18.4M
Sep 2025
$15.4M
Jun 2025
$26.5M
Mar 2025
-$27.3M
Dec 2024
$16.7M
Sep 2024
-$28.0M
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-1.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
-1.3%
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CHYM
FY Dec 2025
-59.0%
FY Dec 2024
-1.7%
FY Dec 2023
n/a
Jun 2026
-0.9%
Mar 2026
-49.7%
Dec 2025
-59.0%
Sep 2025
-50.2%
Jun 2025
-50.0%
Mar 2025
-1.9%
Dec 2024
-1.7%
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-3.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CHYM
FY Dec 2025
-78.1%
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
-3.2%
Mar 2026
-62.4%
Dec 2025
-78.1%
Sep 2025
-63.1%
Jun 2025
-63.5%
Mar 2025
-5.3%
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
33.60x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
23.27x
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing CHYM
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
CHYM ranks highest on institutional and government (92nd percentile) and growth (70th), and lowest on insider conviction (1st), among Financial Services peers.
Profitability
46
Inputs
Return on equity-1.3% · 39 pct, sector of 205
Return on assets-0.9% · 43 pct, sector of 266
Return on invested capitalpre-tax loss, no effective tax rate to apply
Return on capital employed-3.2% · 55 pct, sector of 88
Growth
70
Inputs
Revenue growth, YoY+30.7% · 70 pct, sector of 245
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
0
Inputs
Net Form 4 buying (codes P and S), 180d-$1.1B · 0 pct, sector of 161
Insider buyers, 180d0 · 0 pct, sector of 165
Institutional and government
92
Inputs
Funds adding, latest quarterfewer than five funds report holding it
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quarters$3.2M · 92 pct, sector of 40
Risk and compliance
19
Inputs
Short interest, % of float+10.7% · 19 pct, sector of 390
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Financial health, US patents
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CHYM filings, in plain words
Are Chime Financial insiders buying or selling CHYM?
In the 180 days to 2026-10-27, Chime Financial insiders were net sellers, a net $1.2B across purchases and sales reported on Form 4, by 9 sellers.
Are there planned insider sales of CHYM?
Yes. 31 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $104.7M of stock; the latest, by KING FAMILY TRUST, was filed 2026-10-13.
Read the full summary
In the 180 days to 2026-10-27, Chime Financial insiders were net sellers of CHYM, a net $1.2B across purchases and sales reported on Form 4 by 9 sellers. Most of that figure, $1.1B, came from a holder of 10% or more rather than an officer or director. 4% of the 324 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 31 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $104.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.